

Additional results from clinical phase 1 study

SpectraCure is conducting a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer, using the company's photodynamic therapy (PDT) technology. As previously announced, the fourth patient was treated on February 22nd at the Princess Margaret Cancer Centre in Toronto. During the follow-up after treatment, patients' PSA values are monitored on a regular basis. PSA (prostate-specific antigen) is a blood marker that can indicate the presence of a cancer tumour in the prostate. The last treated patient had a PSA value of 25 mg / ml prior to treatment. At the last visit after treatment, PSA had decreased to 7 mg / ml, with a downward trend. The patient had a much more aggressive form of cancer than previous patients, which is reflected in the high PSA before treatment.

"The clear results are very positive and indicate that the method has a good effect", commented Dr Neil Fleshner, responsible for the study in Toronto.

SpectraCure previously announced that the MRI acquired a week after treatment showed a clear destruction of the prostate gland's blood-rich tissue and tumour area, which is the intended effect of the PDT treatment.

- SpectraCure's treatment technology proves to work well. Our treatment technique has eradicated one of the most aggressive tumours, and the patient is doing well, says Masoud Khayyami, CEO.

It should be emphasized that the main objective of the phase 1 study is to demonstrate that SpectraCure's treatment method is safe and to determine the correct dose level.

The preliminary results also indicate that the method has the intended effect, which is a secondary target for the phase 1 study.

For further information, please contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on March 23th, 2018.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region